Key Points
- Insider Johanna Mercier sold 28,000 Gilead shares at an average of $170.55, totaling about $4.78 million. The sale was made under a pre-arranged Rule 10b5-1 plan; she retained 110,684 shares.
- Gilead reported quarterly earnings of $2.55 per share and revenue of $8.30 billion, beating analyst estimates of $2.19 per share and $7.81 billion, respectively. Revenue rose 6.8% year over year.
- The company declared a quarterly dividend of $0.82 per share, equal to an annualized $3.28 and a 1.9% yield. Analysts’ consensus rating was “Moderate Buy,” with a target price of $171.63.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the company's stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $171.47, for a total transaction of $514,410.00. Following the transaction, the chief financial officer owned 158,096 shares in the company, valued at $27,108,721.12. The trade was a 1.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Gilead Sciences Price Performance
GILD opened at $170.26 on Wednesday. Gilead Sciences, Inc. has a one year low of $116.88 and a one year high of $176.58. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. The company's 50 day simple moving average is $155.90 and its 200-day simple moving average is $142.09. The stock has a market capitalization of $211.18 billion, a P/E ratio of -53.88 and a beta of 0.35.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion during the quarter, compared to analysts' expectations of $7.81 billion. During the same quarter in the previous year, the company posted $2.47 EPS. Gilead Sciences's revenue was up 6.8% on a year-over-year basis. Sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.97 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences's dividend payout ratio (DPR) is presently -103.80%.
Key Headlines Impacting Gilead Sciences
These are some of the GILD headlines that stood out recently:
- Positive Sentiment: Gilead signed royalty-free licenses with three generic manufacturers to support potential future access to investigational Ebola drug obeldesivir in 127 countries. The initiative expands access if the drug is authorized, but is unlikely to generate meaningful near-term sales while it remains experimental. Reuters: Gilead signs generic licensing deals for experimental Ebola drug
- Neutral Sentiment: Gilead completed a new Foster City research center, adding specialized laboratory capacity. This may support research over time, but the completion itself does not indicate a near-term financial impact. Research center completion
- Negative Sentiment: Barclays maintained an equal-weight/hold stance while raising its price target to $160, still below the $170.26 price cited in the stock-performance information. That gap highlights valuation risk after GILD’s strong run. Barclays rating
Institutional Trading of Gilead Sciences
A number of institutional investors have recently bought and sold shares of the business. Holistic Wealth Advisors LLC bought a new stake in Gilead Sciences in the 3rd quarter valued at $328,000. HighMark Wealth Management LLC lifted its holdings in Gilead Sciences by 34.1% during the 3rd quarter. HighMark Wealth Management LLC now owns 291 shares of the biopharmaceutical company's stock valued at $44,000 after purchasing an additional 74 shares during the last quarter. Ancora Advisors LLC lifted its holdings in Gilead Sciences by 5.7% during the 3rd quarter. Ancora Advisors LLC now owns 128,449 shares of the biopharmaceutical company's stock valued at $19,145,000 after purchasing an additional 6,984 shares during the last quarter. Capstone Financial Advisors Inc. acquired a new stake in Gilead Sciences during the 3rd quarter valued at $224,000. Finally, Allworth Financial LP boosted its position in Gilead Sciences by 10.9% during the third quarter. Allworth Financial LP now owns 52,348 shares of the biopharmaceutical company's stock worth $7,802,000 after purchasing an additional 5,156 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on GILD shares. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $170.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th. Zacks Research cut Gilead Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 29th. BMO Capital Markets reiterated an "outperform" rating and issued a $184.00 price objective on shares of Gilead Sciences in a research report on Friday, October 30th. Wells Fargo & Company boosted their price objective on Gilead Sciences from $165.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, October 30th. Finally, Cantor Fitzgerald boosted their price objective on Gilead Sciences from $155.00 to $175.00 and gave the stock an "overweight" rating in a report on Friday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $171.63.
Read Our Latest Stock Report on Gilead Sciences
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].